Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTONASDAQ:ATRANASDAQ:DBVTNASDAQ:MGTXNASDAQ:PRVL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.16-4.9%$1.57$1.15▼$8.70$18.24M1.2987,161 shs47,086 shsATRAAtara Biotherapeutics$0.70-2.1%$0.72$0.20▼$3.02$83.53M0.692.67 million shs865,857 shsDBVTDBV Technologies$0.69-0.2%$0.78$0.65▼$2.37$132.98M0.7550,171 shs40,904 shsMGTXMeiraGTx$4.71-3.1%$5.88$3.49▼$8.35$302.46M1.29154,257 shs121,649 shsPRVLPrevail Therapeutics$23.00$23.01$9.02▼$23.35$787.66M1.59955,800 shsN/ABeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences-0.81%-3.17%-19.21%-36.13%-83.06%ATRAAtara Biotherapeutics-0.54%-0.03%+6.69%+18.50%-75.01%DBVTDBV Technologies-5.74%-2.21%-13.64%-26.66%-56.54%MGTXMeiraGTx-1.42%-7.43%-24.18%-27.68%-8.13%PRVLPrevail Therapeutics0.00%0.00%0.00%0.00%0.00%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences1.153 of 5 stars3.53.00.00.00.60.00.6ATRAAtara Biotherapeutics3.9082 of 5 stars3.02.00.04.72.62.50.6DBVTDBV Technologies1.4605 of 5 stars3.21.00.00.00.03.31.3MGTXMeiraGTx3.7299 of 5 stars3.53.00.04.80.01.70.6PRVLPrevail TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences3.00Buy$19.801,606.90% UpsideATRAAtara Biotherapeutics2.00Hold$28.003,901.14% UpsideDBVTDBV Technologies2.33Hold$5.00625.16% UpsideMGTXMeiraGTx3.00Buy$25.67444.94% UpsidePRVLPrevail TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest APTO, ATRA, MGTX, PRVL, and DBVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$5.003/27/2024APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/1/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $5.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AATRAAtara Biotherapeutics$8.57M9.75N/AN/A($0.97) per share-0.72DBVTDBV Technologies$15.73M8.45N/AN/A$0.73 per share0.94MGTXMeiraGTx$14.02M21.58N/AN/A$2.17 per share2.17PRVLPrevail TherapeuticsN/AN/AN/AN/A$4.85 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$7.72N/AN/AN/AN/A-458.70%-205.30%5/13/2024 (Estimated)ATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)DBVTDBV Technologies-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%5/2/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.23N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)PRVLPrevail Therapeutics-$63.19M-$2.22N/AN/AN/AN/A-55.57%-48.14%N/ALatest APTO, ATRA, MGTX, PRVL, and DBVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/26/2024Q4 2023APTOAptose Biosciences-$1.48-$1.44+$0.04-$1.44N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/APRVLPrevail TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A0.780.78ATRAAtara BiotherapeuticsN/A0.720.65DBVTDBV TechnologiesN/A4.264.26MGTXMeiraGTx0.622.382.38PRVLPrevail TherapeuticsN/A7.567.56OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%ATRAAtara Biotherapeutics70.90%DBVTDBV Technologies71.74%MGTXMeiraGTx67.48%PRVLPrevail Therapeutics86.80%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences9.53%ATRAAtara Biotherapeutics4.50%DBVTDBV Technologies0.71%MGTXMeiraGTx9.70%PRVLPrevail Therapeutics57.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences3115.72 million14.22 millionNo DataATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableDBVTDBV Technologies104192.87 million191.50 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionablePRVLPrevail Therapeutics6634.25 millionN/ANot OptionableAPTO, ATRA, MGTX, PRVL, and DBVT HeadlinesSourceHeadlineEli Lilly's Prevail Therapeutics Ends Gene-Editing Collaboration With Precision BioSciencesprecisionmedicineonline.com - April 17 at 8:13 PMLilly’s Prevail walks away from gene editing collab with Precisionfiercebiotech.com - April 17 at 9:25 AMPrecision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeuticstmcnet.com - April 16 at 6:15 PMPrecision BioSciences to Regain Programs After Prevail Team-Up Endsmarketwatch.com - April 16 at 6:15 PMRoyal Prevail brings fresh ink to Yellow Springsysnews.com - April 10 at 6:47 PMPrevail’s Spring Fashion Show returns May 2readthereporter.com - April 8 at 1:59 PMPrevail Union Opens in North Druid Hillswhatnowatlanta.com - April 2 at 9:21 PMNew England Metal & Hardcore Fest 2024 Lineup: Killswitch Engage and Slaughter to Prevailyahoo.com - April 2 at 4:21 PMBook Review: Insurgent’s Dilemma: A Struggle to Prevailinternationalaffairs.org.au - March 12 at 10:47 AMHalestorm Announce Co-Headlining Tour in 2024 with I Prevailmsn.com - March 6 at 5:04 PMHalestorm, I Prevail Plot 2024 North American Tourexclaim.ca - March 4 at 3:03 PMHalestorm and I Prevail Announce Co-Headline North American Tourrocksound.tv - March 4 at 3:03 PMHalestorm + I Prevail Announce 2024 North American Summer Tourmsn.com - March 4 at 3:03 PMLori Kay Relaunches Management & Production Company Prevail Artist Entertainmentuk.movies.yahoo.com - February 5 at 3:17 PMKansas State basketball vs. Baylor recap: Wildcats prevail in overtime, 68-64cjonline.com - February 2 at 2:20 AMPrevail Bank donates to Uplift Foundationspmetrowire.com - February 1 at 9:26 AMCold, dry weather to prevail in most parts of countryradio.gov.pk - January 16 at 6:24 PMOne big check: Prevail Bank donates to PWYAspmetrowire.com - December 25 at 9:42 AMPrevail Bank raises nearly $15K in matching fundraiserwausaupilotandreview.com - December 19 at 1:54 PMTIGERS PREVAILtrinidadexpress.com - November 28 at 10:33 PMPrevail Bank will match donations, up to $1,000wiscnews.com - November 16 at 8:26 PMLet Logic Prevaildailytimes.com.pk - November 3 at 7:47 AMPrimates Prevail in Teaser for Kingdom of the Planet of the Apes: Watchyahoo.com - November 2 at 5:25 PMSpecialized Prevail 3 helmet review: Ventilation to blow you awaycyclingnews.com - November 2 at 12:25 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptose BiosciencesNASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Atara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.DBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Prevail TherapeuticsNASDAQ:PRVLPrevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.